RxDoctor Payments Data

Tiffany Walker, NP

Adult Health · Las Vegas, NVNPI 1730683319

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 32.9% of the total. That places this record below the midpoint for adult health clinicians in NV, where the typical reported total is $723.

$287in general payments, 2019–2025

Across 15 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$94
  • Biohaven Pharmaceuticals, Inc.$43
  • Takeda Pharmaceuticals U.S.A., Inc.$35
  • Amarin Pharma, Inc.$23
  • Novo Nordisk$20
  • Pfizer$20
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$287 in reported general payments places this provider in the 35th percentile of 90 adult health providers in Nevada.

See all adult health providers in Nevada

Medicare billing

Part B allowed, 2024
$290,411
Medicare patients
20
Services billed
9,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Albuterol Sulfate HfaAlbuterol Sulfate26$646
Atorvastatin Calcium19$458
Lisinopril26$363
Brompheniramine-Pseudoephed-DmBrompheniramine/Pseudoephed/Dm15$362
Losartan Potassium20$331
Promethazine-DmPromethazine/Dextromethorphan25$287
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$246
Metformin Hcl13$225
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$210
Gabapentin19$196
Amlodipine Besylate18$178
Azithromycin69$168
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim20$151
Benzonatate18$143
Triamcinolone Acetonide20$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$20$026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 90 adult health providers in Nevada.

Other adult health in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →